

Press Release

Cellzome publishes discovery of novel and selective inhibitors of Parkinson's disease kinase LRRK2

Heidelberg, Germany, and Cambridge, UK, 3rd August 2011 – Cellzome announced today the publication of an article describing how the Company's unique chemoproteomics drug discovery platform was applied to identify potent and selective inhibitors of LRRK2 in ACS Chemical Biology (Ramsden *et al.* Advanced online publication, DOI:10.1021/cb2002413). The work resulted from a collaboration between Cellzome, Elan (San Francisco, USA) and Prof. Ted Dawson at Johns Hopkins University School of Medicine (Baltimore, USA).

In the article entitled, "Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons", the scientists describe how Cellzome's unique *Kinobeads*[™] platform identified inhibitors of Leucine-rich repeat kinase-2 (LRRK2). Mutations in LRRK2 are the most important cause of familial Parkinson's disease.

Compounds developed by the team prevented injury and death of cultured primary human and rodent neurons carrying the disease mutations. These results provide further pharmacological validation for this therapeutic strategy and will enable more detailed studies of LRRK2-dependent signaling and pathogenesis to accelerate drug discovery.

Carsten Hopf PhD, associate director at Cellzome and senior author of the paper said: "This work demonstrates how chemoproteomics delivers selective inhibitors for the development of novel drug candidates."

- ends -

About Cellzome

Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis.

Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people. For more information please visit: www.cellzome.com

For more information please contact:

Cellzome:

Dr. David Simmons
CSO
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media contact:

Nicole Yost, Jayne Crook
College Hill
Tel: +44 (0)20 7866 7862
cellzome@collegehill.com